%0 Journal Article
%A Buchert, Ralph
%A Huppertz, Hans-Jürgen
%A Wegner, Florian
%A Berding, Georg
%A Brendel, Matthias
%A Apostolova, Ivayla
%A Buhmann, Carsten
%A Poetter-Nerger, Monika
%A Dierks, Alexander
%A Katzdobler, Sabrina
%A Klietz, Martin
%A Levin, Johannes
%A Mahmoudi, Nima
%A Rinscheid, Andreas
%A Quattrone, Andrea
%A Rogozinski, Sophia
%A Rumpf, Jost-Julian
%A Schneider, Christine
%A Stöcklein, Sophia
%A Spetsieris, Phoebe G
%A Eidelberg, David
%A Sabri, Osama
%A Barthel, Henryk
%A Wattjes, Mike P
%A Höglinger, Günter
%T Added value of FDG-PET for detection of progressive supranuclear palsy.
%J Journal of neurology, neurosurgery, and psychiatry
%V 96
%N 3
%@ 0022-3050
%C London
%I BMJ Publishing Group
%M DZNE-2025-00977
%P 287 - 295
%D 2025
%X Diagnostic criteria for progressive supranuclear palsy (PSP) include midbrain atrophy in MRI and hypometabolism in [18F]fluorodeoxyglucose (FDG)-positron emission tomography (PET) as supportive features. Due to limited data regarding their relative and sequential value, there is no recommendation for an algorithm to combine both modalities to increase diagnostic accuracy. This study evaluated the added value of sequential imaging using state-of-the-art methods to analyse the images regarding PSP features.The retrospective study included 41 PSP patients, 21 with Richardson's syndrome (PSP-RS), 20 with variant PSP phenotypes (vPSP) and 46 sex- and age-matched healthy controls. A pretrained support vector machine (SVM) for the classification of atrophy profiles from automatic MRI volumetry was used to analyse T1w-MRI (output: MRI-SVM-PSP score). Covariance pattern analysis was applied to compute the expression of a predefined PSP-related pattern in FDG-PET (output: PET-PSPRP expression score).The area under the receiver operating characteristic curve for the detection of PSP did not differ between MRI-SVM-PSP and PET-PSPRP expression score (p≥0.63): about 0.90, 0.95 and 0.85 for detection of all PSP, PSP-RS and vPSP. The MRI-SVM-PSP score achieved about 13
%K Humans
%K Supranuclear Palsy, Progressive: diagnostic imaging
%K Supranuclear Palsy, Progressive: pathology
%K Female
%K Male
%K Positron-Emission Tomography: methods
%K Fluorodeoxyglucose F18
%K Aged
%K Magnetic Resonance Imaging
%K Retrospective Studies
%K Middle Aged
%K Support Vector Machine
%K Radiopharmaceuticals
%K Brain: diagnostic imaging
%K Brain: pathology
%K Atrophy
%K IMAGE ANALYSIS (Other)
%K MOVEMENT DISORDERS (Other)
%K MRI (Other)
%K PET (Other)
%K SUPRANUCLEAR PALSY (Other)
%K Fluorodeoxyglucose F18 (NLM Chemicals)
%K Radiopharmaceuticals (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:39107038
%2 pmc:PMC12015049
%R 10.1136/jnnp-2024-333590
%U https://pub.dzne.de/record/280893